The bigger hurdles to quality standards for mRNA medicines

The hurdles to quality standards for mRNA medicines have been raised. The quality of mRNA medicines that was allowed in the emergency situation of the Corvit-19 pandemic is no longer acceptable.
https://miyata-bio.net/column/0000386/